Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

ASCO 2014：陆舜谈ALK阳性肺癌的PROFILE 1014研究

2014-05-31 CMT肿瘤 医学论坛网 发表于威斯康星

肺癌ALKASCO陆舜
关注

克唑替尼为初治晚期ALK阳性非鳞NSCLC的一线标准治疗 题目：在晚期ALK阳性非鳞NSCLC患者中克唑替尼与培美曲塞+顺铂/卡铂一线治疗的对比：PROFILE 1014 Ⅲ期研究结果（First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients with adv

克唑替尼为初治晚期ALK阳性非鳞NSCLC的一线标准治疗

题目：在晚期ALK阳性非鳞NSCLC患者中克唑替尼与培美曲塞+顺铂/卡铂一线治疗的对比：PROFILE 1014 Ⅲ期研究结果（First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014).）

摘要号：# 8002

报告时间：2014年6月3日 8:00-11:00 AM CDT(美国中部夏令时间)

报告者：香港中文大学 Tony Mok

Session Title：Lung Cancer - Non-small Cell Metastatic

Session Type：Poster Highlights Session

研究点评

这是在间变性淋巴瘤激酶(ALK)阳性的晚期非小细胞肺癌(NSCLC)患者中进行的一项研究，头对头比较一线给予克唑替尼(Crizotinib)与标准化疗方案培美曲塞+顺铂或培美曲塞+卡铂的疗效。

克唑替尼口服方便，已取得良好疗效，2011年获得美国食品与药物管理局(FDA)的批准，2013年获得我国国家食品药品监督管理总局(CFDA)的批准。

该研究从2011至2013年间纳入343个ALK阳性的非鳞NSCLC初治患者，按照1:1的比例随机接受克唑替尼(250 mg bid，172例)或标准化疗(171例)。主要终点为PFS，次要终点包括客观缓解率(ORR)、总生存(OS)、安全性和患者症状量表的评分。

我所了解到的这是一个阳性结果， 结果不出意料，在ALK阳性的非鳞NSCLC里，克唑替尼显著优于化疗。ORR：74% 对45%;PFS：10.9个月对7.0个月;有68%的患者仍处于随访中，OS结果目前尚未显示出显著的改善(HR=0.821，P=0.1804)，因为化疗的毒性和克唑替尼的口服方便性 此研究可能改变当前临床实践中的标准治疗方案。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938359, encodeId=dc78193835917, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Sep 12 05:41:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987508, encodeId=f0f6198e508dd, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Dec 09 12:41:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601712, encodeId=e1ab1601e1299, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jun 02 12:41:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791493, encodeId=bc2d1e91493be, content=<a href='/topic/show?id=11dc14e11b6' target=_blank style='color:#2F92EE;'>#Profile#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14711, encryptionId=11dc14e11b6, topicName=Profile)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Nov 10 13:41:00 CST 2014, time=2014-11-10, status=1, ipAttribution=)]
    2014-09-12 quxin068

    #ASC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1938359, encodeId=dc78193835917, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Sep 12 05:41:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987508, encodeId=f0f6198e508dd, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Dec 09 12:41:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601712, encodeId=e1ab1601e1299, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jun 02 12:41:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791493, encodeId=bc2d1e91493be, content=<a href='/topic/show?id=11dc14e11b6' target=_blank style='color:#2F92EE;'>#Profile#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14711, encryptionId=11dc14e11b6, topicName=Profile)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Nov 10 13:41:00 CST 2014, time=2014-11-10, status=1, ipAttribution=)]
    2014-12-09 xjy02

    #ALK阳性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1938359, encodeId=dc78193835917, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Sep 12 05:41:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987508, encodeId=f0f6198e508dd, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Dec 09 12:41:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601712, encodeId=e1ab1601e1299, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jun 02 12:41:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791493, encodeId=bc2d1e91493be, content=<a href='/topic/show?id=11dc14e11b6' target=_blank style='color:#2F92EE;'>#Profile#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14711, encryptionId=11dc14e11b6, topicName=Profile)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Nov 10 13:41:00 CST 2014, time=2014-11-10, status=1, ipAttribution=)]
    2014-06-02 sunylz

    #PRO#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1938359, encodeId=dc78193835917, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Sep 12 05:41:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987508, encodeId=f0f6198e508dd, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Dec 09 12:41:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601712, encodeId=e1ab1601e1299, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jun 02 12:41:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791493, encodeId=bc2d1e91493be, content=<a href='/topic/show?id=11dc14e11b6' target=_blank style='color:#2F92EE;'>#Profile#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14711, encryptionId=11dc14e11b6, topicName=Profile)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Mon Nov 10 13:41:00 CST 2014, time=2014-11-10, status=1, ipAttribution=)]
    2014-11-10 hunizi005

    #Profile#

    0

相关资讯

ASCO 2014：T790M的异质性状态影响EGFR-TKI耐药NSCLC的化疗结果

摘要号： 11049 第一作者：郑迪，上海市肺科医院肿瘤科 标题：EGFR-TKI治疗的晚期非小细胞肺癌患者的EGFR-T790M获得性突变的动态无创监测及其异质性发现 背景：EGFR-T790M突变是下一代EGFR-TKI的一个有价值的靶点，大约一半的EGFR突变阳性使用EGFR-TKI的NSCLC患者发生获得性耐药的原因是EGFR-T790M突变。在血浆中

ASCO 2014：修复miR-18a或可预防黑色素瘤继发性耐药

摘要号：#9040 第一作者：郭军，北京大学肿瘤医院肾癌黑色素瘤内科 标题：修复microRNA-18a对继发性耐伊马替尼转移性黑色素治疗作用的提高效应 背景：伊马替尼对携带c-kit基因突变的黑色素瘤具有显著的临床疗效。然而，大多数的黑色素瘤病人对伊马替尼很快产生耐药。在胃肠道间质瘤中已经表明，基因突变、易位、缺失、扩增以及表观遗传变化都参与了伊马替尼的继发

ASCO 2014：用于乳腺癌化疗所致粒缺发热临床预测模型的验证研究

摘要号：#1055 第一作者：陈凯，中山大学附属肿瘤医院放疗科 摘要 背景：本研究致力于证实一个用于早期乳腺癌化疗粒缺发热（FN）的预测模型（Jenkin’s 模型）。 方法：接受新辅助或辅助化疗（蒽环和/或紫衫为基础）的428例患者，没有预防性使用GSF者被纳入本研究。使用Jenkin’s 模型，对中性粒细胞绝对值(ANC)和淋巴细胞绝对值(ALC)

ASCO 2014：卡培他滨联合PA-MSHA治疗转移性乳腺癌安全性良好

标题：铜绿假单胞菌-甘露聚糖-敏感性血清素联合卡培他滨治疗既往使用过蒽环和紫杉醇的HER-2阴性转移性乳腺癌的Ⅱ期临床研究 摘要号：1053 第一作者：吕方芳，复旦大学附属肿瘤医院肿瘤内科 背景：尽管有很多的重要的治疗进展，转移性乳腺癌(MBC)仍具不可治愈性。临床前研究表明，铜绿假单胞菌-甘露聚糖-敏感性血清素（PH-MSHA）对乳腺癌细胞具有抗增殖作用，在

ASCO 2014：内分泌治疗/化疗+VEGFR-TKI治疗晚期乳腺癌的荟萃分析

作者： Yucai Wang 摘要号：#1052 背景：在化疗或者内分泌治疗基础上增加VEGFR-TKI治疗晚期乳腺癌颇有争议。我们评估了相关RCT研究进行荟萃分析，系统评价了在标准治疗的基础上联合VEGFR-TKI在晚期乳腺癌的生存获益和安全性。 方法：我们搜索了PubMed, Web of Science， ASCO和ESMO数据库。纳入的符合条

ASCO 2014：对比6周期ET与8周期EC-T治疗腋窝淋巴结阳性的乳腺癌患者的疗效

摘要号：#1042 标题：6周期ET方案VS4周期ET方案序贯4周期EC-T方案辅助治疗腋窝淋巴结阳性可手术乳腺癌的比较 第一作者：袁芃，中国医学科学院肿瘤医院 背景：了解6周期ET方案和4周期ET方案序贯4周期EC-T方案辅助治疗是否具有相似的疗效，更短的治疗时间和更低的毒副反应。 方法：本研究纳入了腋窝淋巴结阳性可手术乳腺癌患者，随机分为ET方案组

Baidu
map
Baidu
map
Baidu
map